Needham Reiterates Buy on Faeth Therapeutics, Maintains $56 Price Target

Benzinga · 1d ago
Needham analyst Gil Blum reiterates Faeth Therapeutics (NASDAQ:FTH) with a Buy and maintains $56 price target.